Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19-Reference-Cited by-同舟云学术

Randomized Trial of Molnupiravir or Placebo in Patients Hospitalized with Covid-19

Published:2022-01-25 Issue:2 Volume:1 Page:
ISSN:2766-5526
Container-title:NEJM Evidence
language:en
Short-container-title:NEJM Evidence

Author:

Arribas José R.¹,Bhagani Sanjay²,Lobo Suzana M.³,Khaertynova Ilsiyar⁴,Mateu Lourdes⁵,Fishchuk Roman⁶,Park William Y.⁷,Hussein Khetam⁸,Kim Sei Won⁹,Ghosn Jade¹⁰¹¹,Brown Michelle L.¹²,Zhang Ying¹²,Gao Wei¹²,Assaid Christopher¹²,Grobler Jay A.¹²,Strizki Julie¹²,Vesnesky Mary¹²,Paschke Amanda¹²,Butterton Joan R.¹²,De Anda Carisa¹²

Affiliation:

1. Infectious Diseases Unit, Hospital Universitario La Paz-IdiPAZ, Madrid

2. Department of Infectious Diseases, Royal Free Hospital, London

3. Intensive Care Division, Hospital de Base, Faculdade de Medicina de São José do Rio Preto, Brazil

4. Republican Clinical Infectious Diseases Hospital n.a. A.F. Agafonov, Kazan, Russian Federation

5. Infectious Diseases Department, Hospital Universitari Germans Trias i Pujol, Barcelona

6. Central City Clinical Hospital of Ivano-Frankivsk City Council, Ivano-Frankivsk, Ukraine

7. Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington/Valley Medical Center, Renton, WA

8. Infection Control Unit, Rambam Healthcare Campus, Haifa, Israel

9. Department of Internal Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

10. Infectious and Tropical Diseases Department, Assistance Publique–Hôpitaux de Paris Bichat-Claude Bernard Hospital, Paris

11. Institut National de la Santé et de la Recherche Médicale, UMR 1137 ‘Infection, Antimicrobial, Modeling, Evolution’, Université de Paris, Paris

12. Merck & Co., Inc, Kenilworth, NJ

Publisher

Massachusetts Medical Society

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Virology and safety profile of Molnupiravir at three different doses for treatment of SARS‐CoV‐2: a systematic review and meta‐analysis;APMIS;2024-01-30

2. Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19;Journal of Korean Medical Science;2024

3. Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial;Infectious Diseases and Therapy;2023-11-23

4. Uridine–cytidine kinase 2 potentiates the mutagenic influence of the antiviral β-d-N4-hydroxycytidine;Nucleic Acids Research;2023-11-11

5. Promising Repurposed Antiviral Molecules to Combat SARS-CoV-2: A Review;Current Pharmaceutical Biotechnology;2023-11